Physician profile
Raghujit Singh
NPI 1407852452
$2,812.43
in general payments reported to CMS, 2019-2025
16 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $88.43 · 2021: $469 · 2022: $418 · 2023: $693 · 2024: $332 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $754.39 | 2019-2025 | Mavyret, Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $535.30 | 2019-2024 | Xifaxan |
| Gilead Sciences, INC. | $323.25 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $285.76 | 2021-2023 | Remicade, Stelara |
| Boston Scientific Corporation | $247.48 | 2019-2023 | Exalt Model D |
| Janssen Biotech, INC. | $225.96 | 2021-2024 | Stelara, Tremfya, Remicade |
| Medtronic USA, INC. | $125.44 | 2019 | |
| Celgene Corporation | $85.99 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $48.35 | 2019-2020 | |
| Olympus America INC. | $45.19 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $41.37 | 2019-2021 | |
| Ardelyx, INC. | $30.51 | 2024 | Ibsrela |
| Shionogi INC | $22.62 | 2019 | |
| Pfizer INC. | $16.33 | 2024 | |
| Amgen INC. | $13.66 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raghujit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.